Scholar Rock(SRRK) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress - Remains on track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy (SMA) in 4Q 2024 - New data from Phase 2 TOPAZ extension study in patients with nonambulatory SMA showed sustained clinical benefit over 48 months, a continued favorable safety profile with no new safety findings; patient retention rate of over 90% - Phase 2 EMBRAZE proof-of-concept tria ...